Moreover, since PARP inhibitors were initially developed for anti‐cancer therapy, and since adverse effects were also observed in WT retina, the widespread use of compounds like olaparib may raise concerns about potential side effects on the retina. The gene discussed is PARP1; the disease is cancer.